pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody Published date September PRL3-zumab, a first-in-class humanized antibody, was administered in a dose escalation schedule in a The first use of PRL3-zumab in a pediatric patient saw no adverse events. A 28.6% reduction in maximum target lesion diameter was achieved when PRL3-zumab was administered concurrently clinical application of PRL3-zumab in pediatric patients."